Turning the Tide on ALS: New Drug Halts a Key Driver of Motor Neuron Death
- A promising new drug, IFB-088, has demonstrated clinical benefits and a strong safety profile in a Phase 2 trial for patients with a severe form of ALS3, 7.
- Groundbreaking research published in Life Science Alliance reveals the drug directly counteracts the toxic TDP-43 protein clumps found in nearly all ALS cases, rescuing motor neurons1, 5.
- By modulating the body’s core cellular stress response, IFB-088 offers a novel approach that could benefit a broad range of ALS patients, with its developer now seeking partners for pivotal trials1, 7.
For decades, an ALS diagnosis has been a relentless march towards paralysis. Now, a significant ray of hope is piercing through the despair. InFlectis BioScience has unveiled powerful new data on its drug, IFB-088, suggesting it can attack the disease’s devastating progression at its very source.
A recent Phase 2 clinical trial in patients with severe, bulbar-onset ALS showed IFB-088 was not only safe but delivered tangible clinical benefits across multiple endpoints3, 7. Hot on the heels of this success, a groundbreaking study in the journal Life Science Alliance provides the stunning scientific validation: IFB-088 directly tackles the cellular chaos at the heart of the disease1.
The study reveals the drug prevents the mislocalization of TDP-43, a pathological hallmark present in 97% of all ALS patients. By amplifying the body’s own Integrated Stress Response, IFB-088 shields neurons from lethal stress, rescuing motor function and survival in key preclinical models4, 5. Unlike gene-specific treatments, this approach targets a fundamental pathology shared across the ALS population. InFlectis is now urgently seeking partners to launch pivotal studies, racing to turn this scientific breakthrough into a lifeline for patients worldwide1.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.